PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Anthrax
Interventions
BIOLOGICAL

PA83-FhCMB

Trial Locations (1)

20910

Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring

All Listed Sponsors
lead

Fraunhofer, Center for Molecular Biotechnology

INDUSTRY

NCT02239172 - PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine | Biotech Hunter | Biotech Hunter